TY - JOUR T1 - Profile of antimicrobial peptides in the bronchoalveolar lavage of patients with interstitial lung diseases JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.OA1208 VL - 58 IS - suppl 65 SP - OA1208 AU - Ruben Osuna Gómez AU - Sandra Orozco Echevarria AU - Paloma Millán Billi AU - Silvia Vidal Alcorisa AU - Diego Castillo Villegas Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/OA1208.abstract N2 - Aims and objectives: Our aim is to investigate the profile of antimicrobial peptides in bronchoalveolar lavage of patients with ILD.Methods: Bronchoalveolar lavage (BAL) fluids were obtained from ILD’s patients and stored at -20ºC. Depending on the presence of fibrotic findings in the High resolution computerized tomography (HRCT) scan, they were classified as fibrotic vs non-fibrotic. Demographic and clinical parameters were collected. Levels of Lactoferrin, Secretory Leukocyte Peptidase Inhibitor (SLPI) and Lysozyme were measured in BAL samples using specific enzyme-linked immunosorbent assays (ELISA).Results: A total of 64 samples were obtained. We observed that SLPI and Lysozime levels were significantly increased in BAL of non-fibrotic patients (n= 18) when compared with fibrotic patients (n=46) (Figure 1A-B). There were no differences in the levels of Lactoferrin (Figure 1C). Furthermore, we observed a positive correlation between SLPI and Lysozyme levels and lung function values (LFTs) parameters (FVC, DLCO, KCO and FEV). However, there was no correlation between Lactoferrin levels and LFTs.Conclusions: Antimicrobial peptides in BAL of patients with ILD showed a different profile according to the presence of fibrotic features in HRCT scan. Further studies are needed to evaluate if antimicrobial peptides could be a useful biomarker in ILDFootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA1208.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -